A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Activity of NGM282 Administered for 28 Days to Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 21 Nov 2015
At a glance
- Drugs NGM 282 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors NGM Biopharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 17 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Jul 2014 Planned End Date changed from 1 Jun 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.